Skip to main content
. 2015 Jun 19;6(21):18693–18706. doi: 10.18632/oncotarget.4472

Figure 5.

Figure 5

A. Complete response in a 66-year-old patient with prostate cancer treated with 300 mg AMG 208 (bone scans). At baseline, bone metastasis was present at T4 and L1. At week 18, evidence of bone metastasis was not observed. B. Partial response in a 63-year-old patient with prostate cancer treated with 400 mg AMG 208 (18F-FLT-PET and CT scans).